Premedix

The Cardiology Clinic at Premedix is conducting studies aimed at improving outcomes for patients with heart failure and reduced ejection fraction.

• Testing novel agents to lower cardiac stress markers.
• Evaluating combination therapy to prevent hospitalization.
• Comparing new treatments against standard care for mortality reduction.

These trials seek to bring safer, more effective options to individuals living with advanced heart failure in Bratislava.

Research at Premedix focuses on managing high LDL‑C and elevated Lp(a) levels that drive atherosclerotic disease.

• Assessing the impact of a targeted therapy on LDL‑C reduction.
• Exploring treatment for patients with heterozygous familial hypercholesterolemia.
• Investigating agents that lower Lp(a) to decrease major cardiovascular events.

The goal is to provide patients with better lipid control and lower risk of heart attacks and strokes.

The site is evaluating strategies that address the combined burden of type 2 diabetes, high blood pressure and existing cardiovascular disease.

• Testing a dual therapy to reduce cardiovascular death and hospitalizations.
• Measuring the effect of new drugs on major adverse cardiovascular events.
• Studying how metabolic control influences heart failure outcomes.

By targeting multiple risk factors, these studies aim to improve long‑term health for patients with complex cardiometabolic profiles.